Emmanuel Caeymaex

Sep 23, 2024 | healio.com | Jason Laday |Shenaz Bagha |Emmanuel Caeymaex |Joseph F. Merola

You've successfully added to your alerts. You will receive an email when new content is published. Click Here to Manage Email Alerts We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Key takeaways: The FDA has approved bimekizumab-bkzx for three new indications — PsA, AS and non-radiographic axial SpA. The approvals come in the wake of four phase 3 studies.

Oct 18, 2023 | healio.com | Gabrielle Capaldo |Kristen Dowd |Joel M. Gelfand |Emmanuel Caeymaex

Joel M. Gelfand, MD, MSCE The approval of Bimzelx represents a new frontier in what dermatologists can offer patients with moderate to severe psoriasis. It appears to be the most rapid acting and highest efficacy treatment option for moderate to severe psoriasis to date. That said, it is a novel biologic targeting IL-17A and IL-17F. The FDA has given it warnings for suicidal ideation and behavior (1.8% of Bimzelx patients vs. 0.6% of placebo patients), infections (36% of Bimzelx patients vs.